Day: November 17, 2017

  1. Home
  2. Archives: November 2017

Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO

Orphazyme, joint portfolio company of ALS Investment Fund and LSP, raises approximately €80 million in oversubscribed IPO

Recent Posts

  • Apic Bio Announces $40M Series A Financing to Advance Novel Gene Therapies for Rare Genetic Disorders
  • Search for cure against the lethal disease ALS boosted by new investor
  • Orphazyme closes a €14 million Series B Extension
  • Amylyx Pharmaceuticals Receives FDA Orphan Drug Designation for AMX0035 for the Treatment of Amyotrophic Lateral Sclerosis
  • Project ALS and Amylyx Enter Collaboration to Test AMX0035

ROBERT BROWN

Scientific Advisory Board